v3.26.1
Segment Reporting - Segment information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting          
Grant and award revenue $ 2,510 $ 2,169 $ 3,299 $ 2,660  
Total research and development expenses 7,586 6,394 13,697 11,823  
Total general and administrative expenses 5,236 2,619 8,699 5,872  
Impairment expense         $ 5,400
Total operating expenses 12,822 9,013 22,396 17,695  
Operating loss (10,312) (6,844) (19,097) (15,035)  
Other income (expense), net 84,453 (9,451) (22,108) (7,791)  
Net income (loss) 74,141 (16,295) (41,205) (22,826)  
Single Reportable Segment          
Segment Reporting          
Grant and award revenue 2,510 2,169 3,299 2,660  
Expenses not allocated by projects 839 592 1,733 1,112  
Total external research and development expenses 1,289 1,770 2,272 2,514  
Research and development personnel expenses 3,535 2,293 6,160 4,606  
Other research and development expenses 2,762 2,331 5,265 4,703  
Total research and development expenses 7,586 6,394 13,697 11,823  
General and administrative personnel expenses 3,045 1,191 4,507 2,592  
Other general and administrative expenses 2,191 1,428 4,192 3,280  
Total general and administrative expenses 5,236 2,619 8,699 5,872  
Total operating expenses 12,822 9,013 22,396 17,695  
Operating loss (10,312) (6,844) (19,097) (15,035)  
Other income (expense), net 84,453 (9,451) (22,108) (7,791)  
Net income (loss) 74,141 (16,295) (41,205) (22,826)  
Single Reportable Segment | AP-PA02: Non-Cystic Fibrosis Bronchiectasis          
Segment Reporting          
External research and development expenses 16 152 (10) (288)  
Single Reportable Segment | AP-PA02: Cystic Fibrosis          
Segment Reporting          
External research and development expenses 8 14 8 25  
Single Reportable Segment | AP-SA02: Bacteremia          
Segment Reporting          
External research and development expenses $ 426 1,011 $ 541 1,663  
Single Reportable Segment | AP-SA02: Prosthetic Joint Infection          
Segment Reporting          
External research and development expenses   $ 1   $ 2